Jenell Stewart,Renee Heffron,Connie Celum
Jenell Stewart
Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort study [0.03%]
南非接受艾滋病预防服务的妇女使用卡博韦林阴道环和口服暴露前预防药物的情况：一项队列研究
Catherine Elizabeth Martin,Hlologelo Ramatsoma,Glory Chidumwa et al.
Catherine Elizabeth Martin et al.
Background: Introduction of the dapivirine vaginal ring has paved the way for multimethod HIV pre-exposure prophylaxis (PrEP). We aimed to investigate PrEP method preference when offered within integrated, primary care HI...
Global HIV prevention is not on track: how a health systems approach can promote sustainable progress in African countries [0.03%]
全球艾滋病防治工作进展滞后：如何采取卫生系统方法促进非洲国家的可持续发展
Beatrice Matanje,Lillian Chunda,Lilian Otiso et al.
Beatrice Matanje et al.
The expansion of the global HIV response has led to substantial reductions in mortality and new infections over the past two decades. Yet, despite these gains, rates of new HIV infections remain much higher than projected, resulting in long...
Enhancing HIV prevention through systematic community engagement, learning, and response [0.03%]
通过系统性社区参与、学习和应对加强艾滋病预防措施
Ima John-Dada,Lilian Otiso,Stephen Ayisi Addo et al.
Ima John-Dada et al.
Successful uptake of existing and new HIV prevention interventions demands meaningful, systematic, and participatory engagement integrated across the conception, design, implementation, and assessment phases of programming. Despite proven i...
Strengthening nationally led approaches to new product introduction for HIV prevention [0.03%]
加强国家主导的艾滋病预防新产品的推广工作
Hasina Subedar,Nondumiso B Q Ncube,Herbert Kadama et al.
Hasina Subedar et al.
As the pipeline of new HIV prevention technologies (including long-acting injectables, vaginal rings, antibody infusions, and, potentially, vaccines) expands careful planning is needed to ensure these innovations are effectively and equitab...
Nittaya Phanuphak,Jakkrapatara Boonruang,Iskandar Azwa
Nittaya Phanuphak
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial [0.03%]
利福平为基础的结核病治疗期间，用于治疗艾滋病的固定剂量比克替拉韦-恩曲他滨-特诺韦艾拉酚胺每日二次方案（INSIGHT研究）：2b期、开放标签、非随机对照试验
Anushka Naidoo,Kogieleum Naidoo,Marothi P Letsoalo et al.
Anushka Naidoo et al.
Background: The efficacy and safety of bictegravir-based antiretroviral therapy in people with HIV and tuberculosis has not been evaluated. We aimed to evaluate the efficacy, safety, and pharmacokinetics of bictegravir-em...
Eran F Shorer,Raha M Dastgheyb,Leah H Rubin et al.
Eran F Shorer et al.
Parkinsonism is increasingly recognised in people who are ageing with virally suppressed HIV, with bradykinesia emerging earlier and more frequently than in idiopathic Parkinson's disease. Despite effective antiretroviral therapy (ART), stu...
Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysis [0.03%]
七国HIV阳性女性宫颈癌前病变和癌症的年龄分布：系统评价和个体患者数据分析-meta分析
Shona Dalal,Karin Sundström,Ronaldo Silva et al.
Shona Dalal et al.
Background: Women living with HIV have an elevated risk for cervical cancer, present earlier, and have more recurrent human papillomavirus (HPV) infections compared with women without HIV. To update WHO recommendations on...
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study [0.03%]
PEPFAR支持的六个国家中开始或转换为替诺福韦、拉米夫定和多替拉韦疗法的HIV感染者的病毒学及耐药性结局：一项前瞻性队列研究
Jean Bernard Marc,Caitlyn McCarthy,Carole L Wallis et al.
Jean Bernard Marc et al.
Background: A combined regimen of tenofovir disoproxil fumarate, lamivudine, and dolutegravir is widely prescribed for people living with HIV in programmes supported by the US President's Emergency Plan for AIDS Relief (P...